Literature DB >> 2681551

Stage-shift cancer screening model.

R J Connor1, K C Chu, C R Smart.   

Abstract

A stage-shift cancer screening model is developed in the context of a randomized controlled trial (RCT) of cancer screening. In the model, detection by screening causes the time of diagnosis of the cancer to be advanced so that either the stage at diagnosis is shifted from one stage to the next lower one or the stage of diagnosis is unchanged but the cancer is diagnosed earlier in the stage. These are called external and internal stage shifts, respectively. At each stage the extent of the external and internal shifts and any associated mortality benefits are estimated. Further, the model allows the interrelationships of these benefits within and between stages to be delineated. This then allows us to better understand the results of the RCT. Data from a completed breast cancer screening RCT are used to illustrate the application of the model and its value in improving our understanding of the trial's results.

Entities:  

Mesh:

Year:  1989        PMID: 2681551     DOI: 10.1016/0895-4356(89)90050-4

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  10 in total

1.  The impact of the U.S. Preventive Services Task Force guidelines on cancer screening: perspective from the National Cancer Institute.

Authors:  C R Smart
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

2.  Arguments against mammography screening continue to be based on faulty science.

Authors:  Daniel B Kopans
Journal:  Oncologist       Date:  2014-02

3.  Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.

Authors:  Lukas Owens; Roman Gulati; Ruth Etzioni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

4.  Evaluating the breast screening programme: the need for surgical audit.

Authors:  F Kee; D Gorman; W Odling-Smee
Journal:  J R Soc Med       Date:  1993-02       Impact factor: 5.344

5.  Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience.

Authors:  Wenli Dong; Donald A Berry; Therese B Bevers; Shu-Wan Kau; Limin Hsu; Richard L Theriault; Yu Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

6.  Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?

Authors:  Chang-Mo Oh; Jiwon Lim; Yuh Seog Jung; Yeol Kim; Kyu-Won Jung; Seri Hong; Young-Joo Won
Journal:  Cancer Med       Date:  2021-05-12       Impact factor: 4.452

7.  Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer.

Authors:  Shih-Che Shen; Shir-Hwa Ueng; Chan-Keng Yang; Chi-Chang Yu; Yung-Feng Lo; Hsien-Kun Chang; Yung-Chang Lin; Shin-Cheh Chen
Journal:  J Cancer       Date:  2017-07-21       Impact factor: 4.207

8.  The impact of the Polish mass breast cancer screening program on prognosis in the Pomeranian Province.

Authors:  Piotr Woźniacki; Jarosław Skokowski; Krzystof Bartoszek; Anna Kosowska; Leszek Kalinowski; Janusz Jaśkiewicz
Journal:  Arch Med Sci       Date:  2016-06-06       Impact factor: 3.318

9.  An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.

Authors:  Koen Degeling; Nancy N Baxter; Jon Emery; Mark A Jenkins; Fanny Franchini; Peter Gibbs; G Bruce Mann; Grant McArthur; Benjamin J Solomon; Maarten J IJzerman
Journal:  Asia Pac J Clin Oncol       Date:  2021-02-10       Impact factor: 1.926

10.  Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation.

Authors:  Carina M Behr; Hendrik Koffijberg; Koen Degeling; Rozemarijn Vliegenthart; Maarten J IJzerman
Journal:  Eur Radiol       Date:  2022-01-01       Impact factor: 7.034

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.